Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Vir Biotechnology (VIR) will host a conference call on November 4, 2026, to discuss its third-quarter financial results. The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT and will include a ...

SPDR SERIES TRUST-State Street SPDR Portfolio S&P 600 Small Cap ETF 1.16M Sep 30, 2026 0.69% 12,289,326 ...

Vir Biotechnology generated $68.6M in revenue in FY2025, retaining a 100.0% gross margin, operating income reached -$479.3M, and net income was -$438.0M. Diluted earnings per share stood at -$3.16.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.560 between high and low, or 5.58%. For the ...

Vir Biotechnology, Inc. has released encouraging safety and efficacy data from ongoing dose escalation trials for two of its dual-masked T-cell engagers (TCEs): Vir-5818 and Vir-5500. The preliminary ...

More than 7 days of T7-VIR history is available with an upgrade to a Silver (90 days), Gold (1 year), or Business (3 years) subscription. We have all your aviation data needs covered. The ...

2026 Oct 14 7 nights, round-trip from Budapest, Hungary Budapest 2026 Oct 21 7 nights, round-trip from Budapest, Hungary Budapest $3349 2026 Oct 28 10 nights, round-trip from Budapest, Hungary ...